
Staar Surgical (STAA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
42.6M
Gross Profit
28.0M
65.76%
Operating Income
-34.7M
-81.56%
Net Income
-54.2M
-127.29%
EPS (Diluted)
$-1.10
Balance Sheet Metrics
Total Assets
457.4M
Total Liabilities
107.4M
Shareholders Equity
350.0M
Debt to Equity
0.31
Cash Flow Metrics
Operating Cash Flow
-15.7M
Free Cash Flow
-7.2M
Revenue & Profitability Trend
Staar Surgical Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 313.9M | 322.4M | 284.4M | 230.5M | 163.5M |
Cost of Goods Sold | 74.3M | 69.8M | 61.0M | 51.8M | 45.1M |
Gross Profit | 239.6M | 252.7M | 223.4M | 178.6M | 118.4M |
Gross Margin % | 76.3% | 78.4% | 78.5% | 77.5% | 72.4% |
Operating Expenses | |||||
Research & Development | 54.0M | 44.4M | 36.0M | 33.9M | 31.9M |
Selling, General & Administrative | 198.2M | 180.2M | 143.6M | 111.4M | 79.7M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 252.2M | 224.6M | 179.6M | 145.3M | 111.6M |
Operating Income | -12.6M | 28.1M | 43.8M | 33.3M | 6.8M |
Operating Margin % | -4.0% | 8.7% | 15.4% | 14.5% | 4.1% |
Non-Operating Items | |||||
Interest Income | 5.9M | - | - | - | 238.0K |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | -2.4M | -1.4M | -698.0K | -2.0M | 1.3M |
Pre-tax Income | -9.1M | 33.7M | 45.6M | 31.3M | 8.3M |
Income Tax | 11.2M | 12.3M | 5.9M | 3.8M | 2.4M |
Effective Tax Rate % | 0.0% | 36.6% | 12.9% | 12.1% | 28.5% |
Net Income | -20.2M | 21.3M | 39.7M | 27.5M | 5.9M |
Net Margin % | -6.4% | 6.6% | 13.9% | 11.9% | 3.6% |
Key Metrics | |||||
EBITDA | -2.0M | 35.1M | 50.0M | 39.9M | 9.0M |
EPS (Basic) | $-0.41 | $0.44 | $0.81 | $0.52 | $0.13 |
EPS (Diluted) | $-0.41 | $0.43 | $0.79 | $0.50 | $0.12 |
Basic Shares Outstanding | 49125000 | 48523000 | 47987000 | 47210000 | 45605000 |
Diluted Shares Outstanding | 49125000 | 48523000 | 47987000 | 47210000 | 45605000 |
Income Statement Trend
Staar Surgical Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 144.2M | 183.0M | 86.5M | 199.7M | 152.5M |
Short-term Investments | 86.3M | 37.7M | 125.2M | 0 | - |
Accounts Receivable | 77.9M | 94.7M | 62.4M | 43.5M | 35.2M |
Inventory | 43.3M | 35.1M | 24.2M | 17.3M | 18.1M |
Other Current Assets | 980.0K | 762.0K | 811.0K | 636.0K | 1.1M |
Total Current Assets | 367.9M | 365.3M | 311.7M | 271.4M | 216.4M |
Non-Current Assets | |||||
Property, Plant & Equipment | 758.0K | 0 | 0 | 0 | 13.0M |
Goodwill | 3.6M | 3.6M | 3.7M | 3.8M | 3.8M |
Intangible Assets | - | - | 173.0K | 218.0K | 270.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 18.0M | 8.5M | 9.7M | 4.6M | 5.6M |
Total Non-Current Assets | 141.6M | 123.4M | 107.1M | 74.4M | 41.0M |
Total Assets | 509.5M | 488.7M | 418.8M | 345.8M | 257.4M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 16.7M | 13.6M | 11.6M | 8.7M | 7.5M |
Short-term Debt | 3.9M | 4.4M | 3.7M | 3.4M | 4.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 23.0M | 18.0M | 14.8M | 14.3M | 8.9M |
Total Current Liabilities | 70.3M | 65.0M | 51.7M | 48.8M | 41.2M |
Non-Current Liabilities | |||||
Long-term Debt | 34.8M | 31.5M | 27.3M | 28.7M | 6.6M |
Deferred Tax Liabilities | 297.0K | 1.1M | 1.5M | 811.0K | 222.0K |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 41.9M | 37.7M | 31.0M | 38.4M | 19.0M |
Total Liabilities | 112.2M | 102.7M | 82.7M | 87.2M | 60.2M |
Equity | |||||
Common Stock | 493.0K | 488.0K | 482.0K | 477.0K | 464.0K |
Retained Earnings | -67.6M | -47.4M | -68.7M | -111.4M | -135.9M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 397.3M | 386.0M | 336.1M | 258.6M | 197.2M |
Key Metrics | |||||
Total Debt | 38.7M | 35.8M | 31.0M | 32.1M | 10.8M |
Working Capital | 297.6M | 300.2M | 260.0M | 222.6M | 175.2M |
Balance Sheet Composition
Staar Surgical Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -20.2M | 21.3M | 39.7M | 27.5M | 5.9M |
Depreciation & Amortization | 6.9M | 5.1M | 4.5M | 3.6M | 3.1M |
Stock-Based Compensation | 27.2M | 23.5M | 20.4M | 14.6M | 12.1M |
Working Capital Changes | 10.0M | -37.4M | -26.3M | -1.7M | 989.0K |
Operating Cash Flow | 27.4M | 15.7M | 36.0M | 42.6M | 21.3M |
Investing Activities | |||||
Capital Expenditures | -23.4M | -18.2M | -18.1M | -13.6M | -8.4M |
Acquisitions | - | - | - | - | - |
Investment Purchases | -80.2M | -52.3M | -155.7M | 0 | - |
Investment Sales | 44.4M | 144.8M | 17.5M | 0 | - |
Investing Cash Flow | -59.2M | 74.3M | -156.4M | -13.6M | -8.4M |
Financing Activities | |||||
Share Repurchases | -1.5M | -2.1M | 0 | 0 | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | -165.0K | -161.0K | -126.0K | -1.6M | -1.1M |
Financing Cash Flow | -1.7M | -2.3M | -125.0K | -2.9M | -1.6M |
Free Cash Flow | -7.7M | -3.6M | 17.6M | 30.3M | 12.5M |
Net Change in Cash | -33.5M | 87.8M | -120.5M | 26.0M | 11.3M |
Cash Flow Trend
Staar Surgical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
49.73
Forward P/E
35.39
Price to Book
4.09
Price to Sales
6.17
PEG Ratio
-0.15
Profitability Ratios
Profit Margin
-42.45%
Operating Margin
-55.63%
Return on Equity
-25.55%
Return on Assets
-10.71%
Financial Health
Current Ratio
4.94
Debt to Equity
12.04
Beta
0.62
Per Share Data
EPS (TTM)
$-1.93
Book Value per Share
$6.83
Revenue per Share
$4.55
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
staa | 1.4B | 49.73 | 4.09 | -25.55% | -42.45% | 12.04 |
Intuitive Surgical | 171.8B | 66.65 | 9.62 | 16.04% | 28.51% | 0.00 |
Becton, Dickinson | 56.3B | 35.89 | 2.21 | 6.18% | 7.41% | 75.93 |
AtriCure | 1.8B | -39.39 | 3.82 | -7.85% | -7.27% | 16.63 |
Azenta | 1.4B | -9.80 | 0.84 | -9.15% | -16.68% | 3.15 |
Biolife Solutions | 1.2B | -55.77 | 3.37 | -5.66% | -5.92% | 6.86 |
Financial data is updated regularly. All figures are in the company's reporting currency.